Publications by authors named "A Thakkar"

Sleep is increasingly recognized as a significant contributor to the development of cardiovascular disease (CVD). Recent American Heart Association guidelines incorporate sleep duration into the "Life's Essential Eight" framework of ideal cardiovascular health. This article will review the evidence relating sleep duration, regularity, and quality with all-cause and cardiovascular mortality, cardiometabolic syndrome, and coronary artery disease in adults.

View Article and Find Full Text PDF

Aim The primary objective of the study was to evaluate the mid-term implant survivability, rate of revisions, and clinical and functional outcomes following patella resurfacing during total knee arthroplasty (TKA) utilizing posterior stabilized (PS) total knee system (TKS). Methods A prospective, single-arm, multi-center, post-marketing surveillance encompassed patients with end-stage primary knee osteoarthritis (OA) or inflammatory arthritis. The time points of the study included baseline, six weeks, six months, one year, and three years post-operatively.

View Article and Find Full Text PDF

Background: Methamphetamine use is increasing and is associated with development of heart failure (HF). However, clinical characteristics and outcomes have not been well-described.

Objective: To compare outcomes among individuals with HF with and without methamphetamine use in a safety-net setting.

View Article and Find Full Text PDF

Advances in genetic, pharmacologic, and sequencing technology have led to new insight into the role of lymphatics in health and disease. This includes fundamental aspects of the crosstalk between immune cells with cardiac lymphatics. At the interface between leukocytes and lymphatic endothelial cells, myeloid populations are sources of lymphatic growth factors during inflammation.

View Article and Find Full Text PDF
Article Synopsis
  • The LANDMARK trial compared the balloon-expandable Myval transcatheter heart valve (THV) series to the SAPIEN and Evolut THV series in 768 patients to evaluate safety and effectiveness.
  • Results showed that Myval achieved non-inferiority to SAPIEN (24.7% vs 24.1%) and Evolut (24.7% vs 30.0%) regarding a primary composite safety endpoint.
  • Additionally, while Myval had better pressure gradient metrics compared to SAPIEN, Evolut showed slightly higher rates of prosthetic valve regurgitation compared to Myval but no significant difference between Myval and SAPIEN.
View Article and Find Full Text PDF